Treatment with a converting enzyme inhibitor has been shown to stimulate aortic prostaglandin I 2 synthesis. We studied whether converting enzyme inhibitor-stimulated prostaglandin I 2 synthesis might be mediated by kinins. Anesthetized male Sprague-Dawley rats were given a continuous 70-minute infusion of either saline or a kinin analogue antagonist, [DArg°-Hyp A ngiotensin converting enzyme (ACE) inhibi-Z A tors have been found to be effective therapy -/. A . for many forms of hypertension. Although designed to inhibit formation of the potent vasoconstrictor angiotensin II, ACE inhibitors are also effective in treatment of patients with apparently renin (angiotensin)-independent hypertension. 1 Likewise, ACE inhibition can lower blood pressure in animal models of hypertension such as the genetic spontaneously hypertensive rat 2 -4 and deoxycorticosteroneinduced hypertension 5 where the renin-angiotensin system is not considered a major contributing factor to the elevated blood pressure.
kinin degradation when angiotensin is not a critical factor. Scherf et al 6 have shown that a nonspecific inhibitor of kallikrein, aprotinin, can attenuate ACE inhibitor-induced aortic prostaglandin (PG) I 2 biosynthesis. Although kinins are vasodilators, these findings suggest they may mediate synthesis of vasodilator prostaglandins. Kinins, whose endogenous degradation is decreased by ACE (kininase II) inhibition, are potent stimulators of phospholipase A 2 , the rate-limiting enzyme in the synthesis of prostaglandins. It has been suggested that stimulation of vasodilator PG synthesis by ACE inhibitors may account for their antihypertensive action in renin-independent hypertension. Cyclooxygenase inhibition has been shown to diminish the acute hemodynamic effects of captopril. 78 This study will test whether converting enzyme inhibition in vivo leads to altered prostaglandin synthesis in vitro and whether such an effect is mediated by endogenous kinins. Kinins and Endothelial PGI 2   755 with inactin (10 mg/100 g body wt i.p.) (Andrew Lockwood, Inc., Rochester, Minnesota).
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Incubation Protocol
The incubation experiments used aortas from untreated normotehsive rats. The anesthetized rats were opened by a midventral incision to expose the abdominal aorta. Approximately 2 cm was cleaned in situ and excised; the abdominal aorta was then rinsed of luminal blood in medium, cut into four equal pieces, blotted, and pairs placed in incubation flasks containing 6 nil medium. All experiments were carried out using the bicarbonate buffer medium of Churchill and Churchill, 9 which contains 125 mM NaCl, 19 mM NaHCO 3 , 4 mM KC1, 2.6 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 0.8 mM MgSO 4 , and 0.2 g/100 ml glucose. The medium was equilibrated with a 95% O 2 and 5% CO 2 mixture to a pH of 7.4 at a temperature of 37° C. The incubation medium contained 0.1 g/100 ml heat-inactivated bovine serum albumin (BSA) (Difco Laboratories, Detroit, Michigan). The incubation volume (6 ml) was placed in a 25-ml Erlenmeyer flask, continuously gassed with 95% O 2 and 5% CO 2 at 37° C, and shaken at approximately 1 revolution/sec in a Precision shaking water bath (GCA Inc., Chicago, Illinois).
Experiments were carried out by adding either the converting enzyme inhibitor captopril (SQ 14,225, Squibb, Princeton, New Jersey) or enalaprilat (Merck, Sharp & Dohme, Rahway, New Jersey) at molar concentrations of 10~9, 10~6, and 10~4 as well as zero molar (vehicle control). The tissue was incubated under these conditions for 30 minutes, after which time a 1-ml sample was taken for determination of 6-keto PGF) O as described below. The incubation continued for another 30 minutes (1 hour total), at which time a second sample was obtained. A third sample was taken for determination of kinins.
Infusion Protocol
The infusion experiments comprised two phases. In the first phase (in vivo), a PE-50 catheter was placed into the carotid artery for a constant infusion of either saline vehicle at 40 /xl/min or the kinin analogue antagonist of Stewart At the conclusion of the infusion period, the rats were opened by a midventral incision to expose the abdominal aorta and kidneys. Approximately 2 cm of the aorta was removed, rinsed in the medium, cut into four pieces, blotted, and two pieces placed into each of two incubation flasks. Results from these paired flasks were combined to give a single mean value representing each rat.
The kidneys were decapsulated, excised, and split longitudinally. One slice was cut from the lateral outer surface of each half using a StadieRiggs microtome. The slices were bathed in the medium, blotted, and placed into incubation flasks. The samples were incubated for 60 minutes in 10 ml medium containing heat-inactivated albumin as described above. No drugs were added to any of the incubation flasks during this period. At the conclusion of the incubation period, a 200-/xl aliquot was taken for determination of renin concentration and a 1-ml sample taken for prostaglandin determination. All samples were centrifuged and frozen for subsequent analysis. The tissue was removed, ovendried at 56° C for 24 hours, and weighed. All results are expressed as production over the incubation period factored by milligrams dry weight.
Infusion experiments consisted of four distinct groups: 1) rats receiving a saline infusion and given a saline bolus (NaCl/NaCl); 2) rats receiving a saline infusion but subjected to a bolus of enalaprilat (NaCl/CEI); 3) a third group administered a constant infusion of the kinin analogue antagonist and then given a saline bolus (K-Ant/NaCl); and 4) rats given both an analogue antagonist infusion and an enalaprilat bolus (K-Ant/CEI).
These infusion experiments were repeated using the same four-phase protocol, but replacing enalaprilat with captopril as a bolus (22 /Ag/100 g body wt) in 500 fi\ vehicle.
Analytical Methods
Medium renin concentration was determined by radioimmunoassay for generation of angiotensin I (Ang I) based on the method of Haber et al" as previously described. 12 Renin concentration is reflected by nanograms Ang I generated per hour of incubation per milliliter of medium. Renin release is corrected for actual volume sampled and dry tissue weight (ng Ang I/hr/mg/incubation time).
Medium prostaglandin concentration was determined by direct radioimmunoassay using Dray's antibody for PGE 2 (Pasteur Institute, Paris, France) as previously described 1314 and Levine's antibody (Brandeis University, Waltham, Massachusetts) for 6-keto PGF |O using the method of Levine et al 15 as employed in our laboratory. 1314 Each value represents the concentration of PG after 60 minutes of incubation corrected for the dry weight of the tissue sample (pg/mg/hr). All experimental values are compared with concurrent vehicle control experiments. Medium kinin concentration was determined directly by radioimmunoassay as previously described. 16 All data are presented as the arithmetic mean±l SEM. The treatment groups were compared by analysis of variance. Changes or differences were considered significant at p<0.05.
Results
Incubation Protocol
Concentrations of 6-keto PGF )a measured in the tissue incubation medium with various concentra- tions of either captopril or enalaprilat are presented in Table 1 . No concentration of either converting enzyme inhibitor significantly increased prostaglandin concentration after either 30 or 60 minutes of incubation. Nor did we find any measurable kinins in the incubation medium of any of the samples.
Infusion Protocol
The results of the four permutations of the infusion protocol with enalaprilat are presented in Table  2 . There were no significant differences in the basal renin release from renal cortical slices. The 6-keto PGF lQ from cortical slices was marginally determinable in these samples, and there were no differences between the four parameters. These results are not reported. However, cortical PGE 2 was somewhat (20%), though not significantly, elevated after treatment with enalaprilat.
With incubations of the aorta, enalaprilat produced a significant increase in the 6-keto PGF, a (Table 2; Figure 1 ) by some 45%, which was not only greater than incubations from control (NaCl/ NaCl) rats, but also greater than rats treated with enalaprilat and the kinin antagonist (p<0.02). There were no differences between the control group, the group treated with kinin antagonist or enalaprilat and the kinin antagonist. Aortic PGE 2 was not altered by enalaprilat and accounted for only 20% of the total PG measured. In experiments not presented, shorter incubations (15 and 30 minutes) did not result in significant elevations of aortic PG in response to treatment with enalaprilat.
Additional experiments were run using captopril (n=9). Aortic 6-keto PGF la in the control (NaCl/ NaCl) samples equaled 42.4±9.6 ng/mg/hr. The captopril bolus increased the mean 6-keto PGF, a by 40% to 56.9±9.8 ng/mg/hr; however, this increase was not statistically significant. Infusion of the kinin antagonist did not alter 6-keto PGF, O compared with the control group (39.2±7.9 ng/mg/hr), and aortas from rats treated with both captopril and the kinin antagonist were also similar to the control group (35.8±7.2 ng/mg/hr).
Discussion
Treatment of normotensive rats with the ACE (kininase II) inhibitor enalaprilat in vivo significantly increases production of PGI 2 from harvested aortas in vitro. Furthermore, this response can be completely reversed by pretreatment with a competitive analogue antagonist of kinins.
Several investigators have reported that ACE inhibition may result in increased PG synthesis. Vinci et al 17 found that captopril doubled plasma PGE, and Dusing et al 18 reported that captopril increased PGI 2 synthesis from incubated aortic tissue. Scherf et al 6 found that treatment in vivo with ramipril resulted in increased PGI 2 synthesis from aortic strips harvested and incubated in vitro. We have found similar results with enalaprilat and aortic tissue. Also, although our results with captopril were not statistically significant, the trend was toward virtually the same magnitude of change as with enalaprilat, which suggests stimulation of PG 
FIGURE 1. Aortic prostaglandin (PG) I 2 (as indexed by 6-keto PGF, a ) and PGE 2 production after treatment with a bolus of the converting enzyme inhibitor (CEI) enalaprilat or infusion of a kinin analogue antagonist (K-Ant), or both (n=18). *p<0.02.
is due to ACE/kininase II inhibition rather than some unrelated character of the drug. The captopril data are compromised by a smaller number of observations, and also that captopril (on a molar basis) is considered a somewhat weaker drug. However, the data still suggest that captopril, like enalapril, affects PG synthesis by kininase II inhibition. Inhibition of ACE/kininase II leads to decreased metabolism of endogenous kinins, and the vascular endothelial cells are a rich source of the enzyme 19 as well as the primary source of vascular PGI 2 synthesis. 20 Kinins can stimulate phospholipase, and subsequently PG formation. Thus, we hypothesize that ACE inhibition perpetuates endogenous kinin levels, leading to persistent stimulation of PG synthesis. Treatment with captopril results in increased urinary kinin excretion 17 , while ACE inhibitor-induced aortic PGI 2 synthesis can be reversed by aprotinin, a nonspecific inhibitor of kallikrein. 6 Although we found that ACE inhibition led to increased aortic PGI 2 synthesis, we could completely reverse this stimulation by pretreating our rats with a competitive analogue antagonist of kinins. This seems strong evidence that the effect of ACE inhibition on PG synthesis is mediated through kinins.
We found a weak and insignificant effect of enalaprilat in renal cortex. This does not rule out a renal effect of ACE inhibition on PG synthesis, since the cortex is a site for PG dehydrogenases as well as a variety of kininases. In vivo ACE inhibitor-stimulated renal PG synthesis may be better observed in the PGE 2 -rich medulla. Several investigators have suggested that ACE inhibitors may act directly in vitro to stimulate PG synthesis. ACE inhibitors added to incubates of aortic tissue 618 or renal medulla 21 have been reported to result in weak but significant increases in PGI 2 or PGE 2 .
Zusman 21 has found that the sulfhydryl-containing ACE inhibitor captopril can stimulate PGE 2 synthesis in renal medullary cell culture. A captopril analogue that did not inhibit ACE also increased PGE 2 synthesis, whereas another analogue devoid of the sulfhydryl group had no effect. Enalapril (with no sulfhydryl group) had no effect on renal medullary PGE 2 synthesis. Zusman concluded that captopril somehow stimulated PG synthesis independently from ACE inhibition through some action of the sulfhydryl group. However, several sulfhydrylfree ACE inhibitors have been reported to stimulate renal and aortic PG synthesis.
-
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- 23 Alternately, Fujimoto et al 22 have suggested that high concentrations of sulfhydryl-containing ACE inhibitors may inhibit PG synthesis by some mechanism independent of their effect on ACE. Contrary to our results in vivo, our studies employing in vitro incubations of the aorta with captopril and enalaprilat did not show any direct effect of ACE inhibitors on PG synthesis. If we assume kinins mediate the action of ACE inhibitors, then endogenous kinins in vitro would have to be (relatively) increased by such treatments; yet we were unable to find even measurable amounts of kinins in our in vitro preparation. Additionally, kininogen substrate is absent from our blood-free preparation. Zusman 21 reported finding in vitro stimulation of PGE in the renal medulla by captopril but not enalapril. We have not studied renal medulla.
In summary, our data suggest that enalapril may act in part by stimulating vasodilator PGI 2 synthesis, which is reported to be primarily from the vascular endothelial cells where it would be expected to be most important. It is quite possible that this effect is mediated by decreasing degradation of endogenous kinin due to kininase II inhibition, and subsequent kinin stimulation of endothelial phospholipase A 2 . This mechanism may be important in mediating some of the hemodynamic effects of ACE inhibitors.
